Ultime notizie per Catheter Precision (AMEX:VTAK) Azioni

Catheter Precision, Inc. Common Stock

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System) which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

Catheter Precision

Catheter Precision Inc

<p>Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Cathay General to report an <strong>earnings per share</strong> (EPS) of $0.95.</p>
<p>Anticipation surrounds Cathay General's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.02, leading to a 0.65% increase in the share price on the subsequent day.</p>
<p>Here's a look at Cathay General's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.94</td>
<td>0.98</td>
<td>1.06</td>
<td>1.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.96</td>
<td>0.98</td>
<td>1.25</td>
<td>1.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275320_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Cathay General were trading at $46.61 as of October 17. Over the last 52-week period, shares are up 38.67%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CATY/earnings"><strong>To track all earnings releases for Cathay General visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

CATY

An Overview of Cathay General's Earnings

<p>Selective Insurance Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Selective Insurance Gr to report an <strong>earnings per share</strong> (EPS) of $1.65.</p>
<p>Selective Insurance Gr bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company missed EPS by $2.58, which was followed by a 18.18% drop in the share price the next day.</p>
<p>Here's a look at Selective Insurance Gr's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.48</td>
<td>1.84</td>
<td>1.94</td>
<td>1.59</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.10</td>
<td>1.33</td>
<td>1.94</td>
<td>1.51</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-18.0%</td>
<td>-6.0%</td>
<td>-8.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275305_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Selective Insurance Gr were trading at $98.89 as of October 17. Over the last 52-week period, shares are down 3.78%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SIGI/earnings"><strong>To track all earnings releases for Selective Insurance Gr visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SIGI

Selective Insurance Gr's Earnings: A Preview

<p>Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Nucor to report an <strong>earnings per share</strong> (EPS) of $1.49.</p>
<p>Investors in Nucor are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS beat by $0.33, leading to a 1.1% drop in the share price on the subsequent day.</p>
<p>Here's a look at Nucor's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.35</td>
<td>3.65</td>
<td>2.87</td>
<td>4.25</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.68</td>
<td>3.46</td>
<td>3.16</td>
<td>4.57</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-9.0%</td>
<td>7.000000000000001%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275288_0.png" alt="eps graph" /></p>
<h3>Performance of Nucor Shares</h3>
<p>Shares of Nucor were trading at $158.09 as of October 17. Over the last 52-week period, shares are up 12.65%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Opinions on Nucor</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Nucor.</p>
<p>Nucor has received a total of 5 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $170.0, the consensus suggests a potential 7.53% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Steel Dynamics, Reliance and United States Steel, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>The prevailing sentiment among analysts is an Neutral trajectory for Steel Dynamics, with an average 1-year price target of $136.82, implying a potential 13.45% downside.</li>
<li>Reliance received a Outperform consensus from analysts, with an average 1-year price target of $325.0, implying a potential 105.58% upside.</li>
<li>United States Steel received a Buy consensus from analysts, with an average 1-year price target of $42.64, implying a potential 73.03% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Steel Dynamics, Reliance and United States Steel, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucor</td>
<td>Outperform</td>
<td>-15.18%</td>
<td>$1.19B</td>
<td>3.10%</td>
</tr>
<tr>
<td>Steel Dynamics</td>
<td>Neutral</td>
<td>-6.28%</td>
<td>$774.84M</td>
<td>3.49%</td>
</tr>
<tr>
<td>Reliance</td>
<td>Outperform</td>
<td>-6.11%</td>
<td>$1.09B</td>
<td>3.44%</td>
</tr>
<tr>
<td>United States Steel</td>
<td>Buy</td>
<td>-17.77%</td>
<td>$489M</td>
<td>1.62%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Nucor ranks highest in gross profit among its peers. However, it ranks lowest in revenue growth and return on equity. Overall, Nucor's performance is mixed compared to its peers.</p>
<h3>Delving into Nucor's Background</h3>
<p>Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products, and raw materials, the steel mills segment derives maximum revenue. The steel mills segment includes carbon and alloy steel in sheet, bars, structural and plate; steel trading businesses; rebar distribution businesses; and Nucor's equity method investments in NuMit and NJSM.</p>
<h3>Breaking Down Nucor's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Challenges:</strong> Nucor's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-15.18%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Nucor's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>7.95%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>3.1%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.89%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.33</strong>, Nucor adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/NUE/earnings"><strong>To track all earnings releases for Nucor visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Uncovering Potential: Nucor's Earnings Preview

<p>Wintrust Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Wintrust Finl to report an <strong>earnings per share</strong> (EPS) of $2.51.</p>
<p>Investors in Wintrust Finl are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS missed by $0.10 in the last quarter, leading to a 4.98% drop in the share price on the following day.</p>
<p>Here's a look at Wintrust Finl's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.42</td>
<td>2.42</td>
<td>2.49</td>
<td>2.41</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.32</td>
<td>2.89</td>
<td>2.40</td>
<td>2.53</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>0.0%</td>
<td>3.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275276_0.png" alt="eps graph" /></p>
<h3>Wintrust Finl Share Price Analysis</h3>
<p>Shares of Wintrust Finl were trading at $117.01 as of October 17. Over the last 52-week period, shares are up 56.66%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/WTFC/earnings"><strong>To track all earnings releases for Wintrust Finl visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


WTFC

A Preview Of Wintrust Finl's Earnings

<p>Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Cathay General to report an <strong>earnings per share</strong> (EPS) of $0.95.</p>
<p>The announcement from Cathay General is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS beat by $0.02 in the last quarter, leading to a 0.65% increase in the share price on the following day.</p>
<p>Here's a look at Cathay General's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.94</td>
<td>0.98</td>
<td>1.06</td>
<td>1.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.96</td>
<td>0.98</td>
<td>1.25</td>
<td>1.13</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-5.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275266_0.png" alt="eps graph" /></p>
<h3>Tracking Cathay General's Stock Performance</h3>
<p>Shares of Cathay General were trading at $46.61 as of October 17. Over the last 52-week period, shares are up 38.73%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CATY/earnings"><strong>To track all earnings releases for Cathay General visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Glimpse of Cathay General's Earnings Potential

<p>Selective Insurance Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGI#NASDAQ">SIGI</a>) will release its quarterly earnings report on Monday, 2024-10-21. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Selective Insurance Gr to report an <strong>earnings per share</strong> (EPS) of $1.65.</p>
<p>The market awaits Selective Insurance Gr's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Earnings Track Record</h3>
<p>The company's EPS missed by $2.58 in the last quarter, leading to a 18.18% drop in the share price on the following day.</p>
<p>Here's a look at Selective Insurance Gr's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.48</td>
<td>1.84</td>
<td>1.94</td>
<td>1.59</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.10</td>
<td>1.33</td>
<td>1.94</td>
<td>1.51</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-18.0%</td>
<td>-6.0%</td>
<td>-8.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275247_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Selective Insurance Gr were trading at $98.89 as of October 17. Over the last 52-week period, shares are down 3.61%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SIGI/earnings"><strong>To track all earnings releases for Selective Insurance Gr visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Look at Selective Insurance Gr's Upcoming Earnings Report

<p>Wells Fargo  analyst Eric Luebchow   maintains Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) with a Equal-Weight and raises the price target from $100 to $105.</p>


News

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Crown Castle, Raises Price Target to $105

<p>Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) is preparing to release its quarterly earnings on Monday, 2024-10-21. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Nucor to report an <strong>earnings per share</strong> (EPS) of $1.49.</p>
<p>Nucor bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS beat by $0.33 in the last quarter, leading to a 1.1% drop in the share price on the following day.</p>
<p>Here's a look at Nucor's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.35</td>
<td>3.65</td>
<td>2.87</td>
<td>4.25</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.68</td>
<td>3.46</td>
<td>3.16</td>
<td>4.57</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>-9.0%</td>
<td>7.000000000000001%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729275211_0.png" alt="eps graph" /></p>
<h3>Tracking Nucor's Stock Performance</h3>
<p>Shares of Nucor were trading at $158.09 as of October 17. Over the last 52-week period, shares are up 12.58%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Perspectives on Nucor</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Nucor.</p>
<p>The consensus rating for Nucor is Outperform, based on 5 analyst ratings. With an average one-year price target of $170.0, there's a potential 7.53% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Steel Dynamics, Reliance and United States Steel, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Steel Dynamics, with an average 1-year price target of $136.82, suggesting a potential 13.45% downside.</li>
<li>The consensus among analysts is an Outperform trajectory for Reliance, with an average 1-year price target of $325.0, indicating a potential 105.58% upside.</li>
<li>The prevailing sentiment among analysts is an Buy trajectory for United States Steel, with an average 1-year price target of $42.64, implying a potential 73.03% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Steel Dynamics, Reliance and United States Steel, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nucor</td>
<td>Outperform</td>
<td>-15.18%</td>
<td>$1.19B</td>
<td>3.10%</td>
</tr>
<tr>
<td>Steel Dynamics</td>
<td>Neutral</td>
<td>-6.28%</td>
<td>$774.84M</td>
<td>3.49%</td>
</tr>
<tr>
<td>Reliance</td>
<td>Outperform</td>
<td>-6.11%</td>
<td>$1.09B</td>
<td>3.44%</td>
</tr>
<tr>
<td>United States Steel</td>
<td>Buy</td>
<td>-17.77%</td>
<td>$489M</td>
<td>1.62%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Nucor ranks at the top for Gross Profit and Return on Equity among its peers. However, it ranks at the bottom for Revenue Growth.</p>
<h3>About Nucor</h3>
<p>Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products, and raw materials, the steel mills segment derives maximum revenue. The steel mills segment includes carbon and alloy steel in sheet, bars, structural and plate; steel trading businesses; rebar distribution businesses; and Nucor's equity method investments in NuMit and NJSM.</p>
<h3>A Deep Dive into Nucor's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Nucor's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-15.18%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> Nucor's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>7.95%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Nucor's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>3.1%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Nucor's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.89%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.33</strong>.</p>
<p><a href="https://www.benzinga.com/quote/NUE/earnings"><strong>To track all earnings releases for Nucor visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Peek at Nucor's Future Earnings

<p><strong>Tandem Diabetes Care, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tndm#NASDAQ">TNDM</a>) has been on a downward spiral lately with significant selling pressure. After declining 21.7% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.</p>
<h3>How To Determine If A&nbsp;Stock Is Oversold</h3>
<p>We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.</p>
<p>RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.</p>
<p>Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock&#39;s price is reaching a point of reversal.</p>
<p>So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.</p>
<p>However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.</p>
<h3>Why TNDM Could Bounce Back Before Long</h3>
<p>The RSI reading of 29.87 for TNDM is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.</p>
<p><img alt="3-month RSI Chart for TNDM" class="chart" src="https://staticx-tuner.zacks.com/images/articles/charts/yseop/544/TNDM_RCI14.jpeg" style="width:624px" title="" /></p>
<p>The RSI value is not the only factor that indicates a potential turnaround for the stock in the near term. On the fundamental side, there has been strong agreement among the sell-side analysts covering the stock in raising earnings estimates for the current year. Over the last 30 days, the consensus EPS estimate for TNDM has increased 0.1%. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.</p>
<p><a href="https://www.zacks.com/stock/news/2353052/down-21-69-in-4-weeks-here-s-why-tandem-diabetes-care-tndm-looks-ripe-for-a-turnaround?cid=CS-BENZ-FT-tale_of_the_tape|rsi-2353052">To read this article on Zacks.com click here.</a></p>


Health Care

Markets

Trading Ideas

General

TNDM

Down -21.69% In 4 Weeks, Here's Why Tandem Diabetes Care Looks Ripe For A Turnaround

<p>Wells Fargo  analyst Donald Fandetti   maintains Discover Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) with a Equal-Weight and raises the price target from $152 to $160.</p>


Wells Fargo Maintains Equal-Weight on Discover Finl, Raises Price Target to $160

<p>Wells Fargo  analyst Mike Mayo   maintains M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) with a Underweight and raises the price target from $165 to $190.</p>


Wells Fargo Maintains Underweight on M&T Bank, Raises Price Target to $190

<p>"Cannabis vaping is very different from nicotine vaping; it should be subject to different rules and restrictions." That's according to <strong>Steven Przybyia,</strong> chief legal officer at <strong>Ispire Technology Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>), who joined three other experts on the stage in Chicago at the <a href="https://www.benzinga.com/events/cannabis-conference/"><strong>Benzinga Cannabis Capital Conference</strong></a>. Yet, Przybyia says applying nicotine industry technologies to cannabis for enhanced safety measures, including age-gating technology, is a viable option.</p>
<p>During the conference panel, moderated by <strong>Shauntel Ludwig,</strong> CEO of <strong>Synergy Innovation</strong>, experts provided an overview of trends and innovations in the cannabis vaporization space. <strong>Tim Conder, </strong>CEO of <strong>TILT Holdings Inc.</strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TLLTF#OTC">TLLTF</a>),<strong> Alex Kwon, </strong>CEO and founder of <strong>ACTIVE</strong>, <a href="https://www.benzinga.com/markets/cannabis/24/04/38417419/new-name-same-quality-cannabis-vapor-tech-leader-avd-rebrands-as-active">formerly</a> <strong>Advanced Vapor Devices</strong> and <strong>Nicholas Kovacevich</strong>, strategic advisor at <strong>CCELL </strong>also joined the panel titled &#8220;Vape Innovation Masterclass: Cost-Effective, Quality Tech for a Global Market.&#8221; </p>
<p>Panelists highlighted the importance of consumer focus, investment in research and development (R&amp;D) sector and the integration of safety measures, positioning these elements as foundational for sustainable growth in the industry.</p>
<p><strong>Read Also:</strong> <strong><a href="https://www.benzinga.com/markets/cannabis/24/10/41297836/exclusive-tracking-every-cannabis-deal-is-a-lot-of-fun-says-financial-expert-behind-essential-in">EXCLUSIVE: Tracking Every Cannabis Deal Is &#8216;A Lot Of Fun,&#8217; Says Financial Expert Behind Essential Investor Tool</a></strong></p>
<h3 class="wp-block-heading">The Importance Of Consumer Safety</h3>
<p>Przybyia shed light on age-gating technology illustrating the growing emphasis on safety within the industry.</p>
<p>He spoke about the development of a Bluetooth-enabled age-gating system that biometrically verifies user age before allowing device activation. Przybyia highlighted the potential of this technology for public health, linking it to regulatory challenges in the nicotine market and demonstrating how similar strategies can be adapted for cannabis.</p>
<p>"This is a technology that we&#8217;re using from the nicotine space that we think has a lot of application from a safety, from a public health perspective in the cannabis space," Przybyia said. "If you want to sell lawfully, in the U.S, you need to show that youth access is restricted."</p>
<p>Przybyia also touched on the vaping industry association called <strong>VapeSAFER</strong>. The initiative focuses on self-regulation and establishing quality standards within the vapor industry to combat low-quality products entering the market and advocate for tailored regulations.</p>
<ul>
<li><strong><em>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</em></strong></li>
</ul>
<p>"We want to promulgate our own standards," he said. "We want to self-police ourselves. We want to actively engage with trade groups, associations Regulators and the FDA."</p>
<p>That said, ACTIVE&#8217;s Kwon highlighted the importance of standardized testing and understanding product ingredients to ensure safety and quality. He added that the cannabis vaping industry should not be overshadowed by regulations designed for nicotine products.</p>
<p>"We probably don&#8217;t want e-cigarettes, big tobacco blanketing the regulations around cannabis," Kwon said. </p>
<p>The cannabis vapor industry needs to ensure to be "at the seated table when a regulatory change is there because the sensible policy is going to be super important to make sure that there is a constant sustainable future for all the hard work that all the companies..because it&#8217;s a massive category that I think it&#8217;s just too important of a topic where we just kind of let Others kind of dictate," Kwon said.</p>
<h3 class="wp-block-heading">Innovation As Competitive Edge</h3>
<p>All panelists agreed that continuous innovation is a key to success in the rapidly evolving cannabis industry.</p>
<p>TILT&#8217;s Konder said brands must leverage unique product features to attract consumers' interest and loyalty. </p>
<p>"Innovation for us is paramount and it&#8217;s become paramount for brands not just over the past several years, but right now today to differentiate in the market," he said. "Innovation is how a brand can stand apart from its competitors on the Shelf and really sort of earn a place in consumer&#8217;s hearts."</p>
<p>CCELL&#8217;s Kovacevich emphasized CCELL&#8217;s commitment to research, adding that it's necessary to invest in R&amp;D substantially to push the boundaries of what's possible in vaporization technology.</p>
<p>He also recalled navigating the vape crisis of 2019, where he faced challenges in an attempt to raise funds due to public health concerns.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>EXCLUSIVE: <a href="https://www.benzinga.com/markets/cannabis/24/10/41317886/exclusive-emotional-connection-with-consumers-is-secret-sauce-for-any-brand-to-prosper-its-same-">Emotional Connection With Consumers Is Secret Sauce For Any Brand To Prosper, It&#8217;s Same With Cannabis, Experts Say</a></strong></li>
</ul>


Cannabis

Events

Exclusives

ISPR

TLLTF

EXCLUSIVE: What It Takes To Thrive In Cannabis Vape Space - Lessons Learned From Industry Trailblazers

WIIM

Vicinity Motor Corp shares are trading lower after the company announced PricewaterhouseCoopers resigned as its auditor and expects the BC Securities Commission will cease the trading of its common stock by Monday, October 21.

<p>Uranium Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UEC#AMEX">UEC</a>) has outperformed the market over the past 5 years by 38.33% on an annualized basis producing an average annual return of 52.69%. Currently, Uranium Energy has a market capitalization of $3.52 billion. </p>
<p><strong>Buying $100 In UEC:</strong> If an investor had bought $100 of UEC stock 5 years ago, it would be worth <strong>$822.00</strong> today based on a price of $8.55 for UEC at the time of writing.</p>
<h3>Uranium Energy's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729274760_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$100 Invested In This Stock 5 Years Ago Would Be Worth $800 Today

<p>In the last three months, 6 analysts have published ratings on Petco Health and Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Petco Health and Wellness and provided 12-month price targets. The average target is $4.25, accompanied by a high estimate of $5.50 and a low estimate of $3.00. This upward trend is apparent, with the current average reflecting a 3.16% increase from the previous average price target of $4.12.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729274760_0_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A comprehensive examination of how financial experts perceive Petco Health and Wellness is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$5.50</td>
<td>$5.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$4.50</td>
<td>$4.00</td>
</tr>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$4.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Steven Shemesh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$3.50</td>
<td>$3.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$3.00</td>
<td>$2.75</td>
</tr>
<tr>
<td>Seth Basham</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Petco Health and Wellness. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Petco Health and Wellness compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Petco Health and Wellness's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Petco Health and Wellness's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WOOF/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Petco Health and Wellness analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Petco Health and Wellness</h2>
<p>Petco Health and Wellness Co Inc is a pet health and wellness company focused on improving the lives of pets, pet parents, and its partners with approximately 1,423 pet care centers offering pet care products such as puppy food, treats, nutrition, and supplies through retail outlets and online platforms. The company generates revenue from the sale of products and services such as dog and cat food, supplies, and companion animals, among others.</p>
<h3>Petco Health and Wellness's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Petco Health and Wellness's revenue growth over 3 months faced difficulties. As of 31 July, 2024, the company experienced a decline of approximately <strong>-0.46%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Petco Health and Wellness's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-1.63%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Petco Health and Wellness's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-2.16%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-0.47%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Petco Health and Wellness's debt-to-equity ratio is below the industry average. With a ratio of <b>2.64</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


WOOF

Petco Health and Wellness Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

<p>Analysts' ratings for Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Xometry, presenting an average target of $25.0, a high estimate of $32.00, and a low estimate of $12.00. This current average has increased by 3.31% from the previous average price target of $24.20. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729274750_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of Xometry among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Troy Jensen</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Nicholas Jones</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Xometry. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Xometry compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Xometry's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Capture valuable insights into Xometry's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/XMTR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Xometry analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Xometry Better</h2>
<p>Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of the revenue is earned from the U.S. segment.</p>
<h3>Xometry: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Xometry displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>19.45%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Xometry's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-10.33%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-4.31%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Xometry's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-2.0%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Xometry's debt-to-equity ratio is below the industry average. With a ratio of <b>0.94</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


XMTR

Beyond The Numbers: 5 Analysts Discuss Xometry Stock

<p>4 analysts have expressed a variety of opinions on Bank OZK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZK#NASDAQ">OZK</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $52.75, a high estimate of $63.00, and a low estimate of $48.00. This current average reflects an increase of 7.65% from the previous average price target of $49.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729274685_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Bank OZK among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Scouten</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$63.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$48.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Manan Gosalia</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$51.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Brandon King</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$49.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bank OZK. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Bank OZK compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Bank OZK's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Bank OZK's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/OZK/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Bank OZK analyst ratings.</strong></a></p>
<h2>Delving into Bank OZK's Background</h2>
<p>Bank OZK is a bank holding company that owns and operates a community bank, Bank of the Ozarks. The bank operates offices in Arkansas, Georgia, Florida, North Carolina, Texas, California, New York and Mississippi. It provides a range of banking services which include deposit services such as checking, savings, money market, time deposit and individual retirement accounts to loan services like real estate, consumer, commercial and industrial loans. Apart from providing traditional banking products and services it also provides treasury management, trust and wealth management, financial planning, online banking and other related services.</p>
<h3>Breaking Down Bank OZK's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Bank OZK's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>7.19%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>41.63%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Bank OZK's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>3.47%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Bank OZK's ROA excels beyond industry benchmarks, reaching <strong>0.48%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Bank OZK's debt-to-equity ratio is below the industry average. With a ratio of <b>0.17</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Navigating 4 Analyst Ratings For Bank OZK

<p>27 analysts have expressed a variety of opinions on Diamondback Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">16</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Diamondback Energy, presenting an average target of $218.85, a high estimate of $255.00, and a low estimate of $154.00. This current average has decreased by 2.26% from the previous average price target of $223.92. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729274666_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of Diamondback Energy by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$218.00</td>
<td>$219.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$233.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Tim Rezvan</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$216.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$252.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Paul Cheng</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$225.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Phillip Jungwirth</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$215.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$182.00</td>
<td>-</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$219.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$209.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$220.00</td>
<td>$255.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$223.00</td>
<td>$247.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$198.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$185.00</td>
<td>-</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$237.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$247.00</td>
<td>$245.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$240.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$230.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$245.00</td>
<td>$257.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$216.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$255.00</td>
<td>$249.00</td>
</tr>
<tr>
<td>Subash Chandra</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$154.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Kalei Akamine</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$201.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Diamondback Energy. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Diamondback Energy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Diamondback Energy's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Diamondback Energy's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FANG/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Diamondback Energy analyst ratings.</strong></a></p>
<h2>Delving into Diamondback Energy's Background</h2>
<p>Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2023, the company reported net proven reserves of 2.2 billion barrels of oil equivalent. Net production averaged about 448,000 barrels per day in 2023, at a ratio of 59% oil, 21% natural gas liquids, and 20% natural gas.</p>
<h3>Diamondback Energy's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Diamondback Energy's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>29.34%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Diamondback Energy's net margin excels beyond industry benchmarks, reaching <strong>33.48%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>4.83%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Diamondback Energy's ROA excels beyond industry benchmarks, reaching <strong>2.54%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.69</strong>, Diamondback Energy faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


FANG

Evaluating Diamondback Energy: Insights From 27 Financial Analysts

<p><a href="https://news.bloomberglaw.com/banking-law/cfpbs-buy-now-pay-later-rule-hit-with-fintech-group-lawsuit" title="https://news.bloomberglaw.com/banking-law/cfpbs-buy-now-pay-later-rule-hit-with-fintech-group-lawsuit">https://news.bloomberglaw.com/banking-law/cfpbs-buy-now-pay-later-rule-hit-with-fintech-group-lawsuit</a></p>


AFRM

PYPL

'CFPB's Rule Aims To Treat Buy Now, Pay Later Like Credit Cards' - Bloomberg

<p>Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) underwent analysis by 13 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $20.62, a high estimate of $33.50, and a low estimate of $10.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.84%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729274608_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A clear picture of Unity Software's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Kuntarich</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Underperform</td>
<td>$15.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Michael Pachter</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Matthew Cost</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$23.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Mike Hickey</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Sell</td>
<td>$10.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.50</td>
<td>$26.00</td>
</tr>
<tr>
<td>Michael Pachter</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$33.50</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Michael Pachter</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$33.50</td>
<td>$33.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Unity Software. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Unity Software compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Unity Software's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Unity Software's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/U/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Unity Software analyst ratings.</strong></a></p>
<h2>About Unity Software</h2>
<p>Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.</p>
<h3>Unity Software: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Unity Software's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-15.79%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Unity Software's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-27.95%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Unity Software's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-3.94%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Unity Software's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-1.87%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Unity Software's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.7</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For Unity Software's Future

Ra Medical Systems reports Q4 results

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Catheter Precision, Inc. Common Stock</strong> (NYSEMKT:<span><a href="https://investorplace.com/stock-quotes/vtak-stock-quote/"><strong>VTAK</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Catheter Precision, Inc. Common Stock reported earnings per share of -36 cents. This was above the analyst estimate for EPS of -42 cents.</li><li>The company reported revenue of $82,000.</li><li>This was 54.44% worse than the analyst estimate for revenue of $180,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/vtak-stock-earnings-catheter-precision-inc-common-stock-for-q1-of-2024/">VTAK Stock Earnings: Catheter Precision, Inc. Common Stock Beats EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

VTAK Stock Earnings: Catheter Precision, Inc. Common Stock Beats EPS, Misses Revenue for Q1 2024

Catheter Precision (VTAK) has shared an update. Catheter Precision, Inc. stockholders showed active participation in their annual meeting where the...

Catheter Precision Shareholders Approve Key Corporate Changes

These are the upcoming stock splits for the week of July 15 to July 19, based on TipRanks' Stock Splits Calendar. A stock split is a corporate acti...

Upcoming Stock Splits This Week (July 15 to July 19) – Stay Invested

Catheter Precision announces effectiveness of 1-for-10 reverse stock split

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>It&rsquo;s time to dive into the biggest pre-market stock movers for Wednesday morning as we check out all of the hottest news to start the day with!</p>



<p>Moving stocks this morning a partnerships, a public offering, clinical trial news and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Dermata Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/"><strong>DRMA</strong></a>) stock is rocketing more than 123% alongside heavy pre-market trading.</li>



<li><strong>Nuzee </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/"><strong>NUZE</strong></a>) shares are soaring over 75% with strong early morning trading.</li>



<li><strong>Hoth Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/"><strong>HOTH</strong></a>) stock is surging more than 45% <a href="https://www.nasdaq.com/press-release/hoth-therapeutics-partners-lts-therapy-systems-accelerate-novel-alzheimers-treatment">on a new partnership</a> to develop its Alzheimer&rsquo;s treatment.</li>



<li><strong>Allarity Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/"><strong>ALLR</strong></a>) shares are increasing over 44% after encouraging investors to <a href="https://finance.yahoo.com/news/allarity-encourages-shareholders-vote-reverse-100000785.html">vote for a reverse stock split</a>.</li>



<li><strong>Regencell Bioscience</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/"><strong>RGC</strong></a>) stock is heading more than 33% higher alongside strong pre-market trading.</li>



<li><strong>Pieris Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/pirs-stock-quote/"><strong>PIRS</strong></a>) shares are rising over 28% after <a href="https://www.nasdaq.com/press-release/palvella-therapeutics-and-pieris-pharmaceuticals-announce-definitive-merger-agreement">announcing a merger agreement</a>.</li>



<li><strong>Bone Biologics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/"><strong>BBLG</strong></a>) stock is jumping more than 23% with heavy early morning trading today.</li>



<li><strong>NewGenIvf</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/nivf-stock-quote/"><strong>NIVF</strong></a>) shares are climbing over 22% after providing a <a href="https://www.nasdaq.com/press-release/newgenivf-provides-update-potential-reverse-merger-covirix-2024-07-23">reverse merger update</a>.</li>



<li><strong>Perfect Moment</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/pmnt-stock-quote/"><strong>PMNT</strong></a>) stock is getting a close to 19% boost after announcing a <a href="https://www.nasdaq.com/press-release/perfect-moment-teams-quiet-platforms-establish-distribution-center-us-2024-07-22">distribution center agreement</a>.</li>



<li><strong>Catheter Precision</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vtak-stock-quote/"><strong>VTAK</strong></a>) shares are up more than 16% without any clear news this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Azitra</strong>&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/"><strong>AZTR</strong></a>) stock is crashing over 73% but only <a href="https://investorplace.com/2024/07/why-is-azitra-aztr-stock-up-315-today/">after a massive rally yesterday</a>.</li>



<li><strong>Conn&rsquo;s </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/"><strong>CONN</strong></a>) shares are plummeting 28% on <a href="https://www.12newsnow.com/article/news/local/texas/conns-reportedly-planning-mass-closures/502-4db60564-6fdd-4ffa-ae26-899bec91f75c">reports of impending store closures</a>.</li>



<li><strong>ATI Physical Therapy</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/atip-stock-quote/"><strong>ATIP</strong></a>) stock is diving more than 25% without any obvious news this morning.</li>



<li><strong>Verastem </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/"><strong>VSTM</strong></a>) shares are tumbling over 25% on a <a href="https://finance.yahoo.com/news/verastem-oncology-announces-proposed-public-200500583.html">proposed public offering</a>.</li>



<li><strong>Agape ATP</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/atpc-stock-quote/"><strong>ATPC</strong></a>) stock is taking an almost 24% beating after a rally yesterday.</li>



<li><strong>AtlasClear </strong>(NYSEMKT:<a href="https://investorplace.com/stock-quotes/atch-stock-quote/"><strong>ATCH</strong></a>) shares are sliding more than 22% despite a lack of news on Wednesday.</li>



<li><strong>Sage Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/sage-stock-quote/"><strong>SAGE</strong></a>) stock is dropping over 22% after reporting <a href="https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-topline-results-phase-2-kinetic-2-study-sage">Phase 2 topline results</a>.</li>



<li><strong>Volato </strong>(NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/"><strong>SOAR</strong></a>) shares are decreasing more than 21% <a href="https://www.nasdaq.com/press-release/volato-updates-fractional-program-additional-differentiated-benefits-2024-07-23">after a recent rally</a>.</li>



<li><strong>Chijet Motor</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/cjet-stock-quote/"><strong>CJET</strong></a>) stock is slipping over 19% following yesterday&rsquo;s rally.</li>



<li><strong>Salarius Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/"><strong>SLRX</strong></a>) shares close out our pre-market stock movers down more than 19% after a rally yesterday.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

An update from Catheter Precision (VTAK) is now available. On July 24, 2024, a company successfully converted all outstanding Series A Convertible ...

Catheter Precision Converts Series A Preferred Stock

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Catheter Precision, Inc. Common Stock</strong> (NYSEMKT:<span><a href="https://investorplace.com/stock-quotes/vtak-stock-quote/"><strong>VTAK</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Catheter Precision, Inc. Common Stock reported earnings per share of -$5.57.</li><li>The company reported revenue of $93,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/vtak-stock-earnings-catheter-precision-inc-common-stock-for-q2-of-2024/">VTAK Stock Earnings: Catheter Precision, Inc. Common Stock Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Comments

Catheter Precision

Notizie

Ultime notizie per Catheter Precision (AMEX:VTAK) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO